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Abstract Thimerosal is an organic mercury (Hg)-containing
compound (49.55%Hg byweight) historically added tomany
multi-dose vials of vaccine as a preservative. A hypothesis
testing case-control study evaluated automated medical re-
cords in the Vaccine Safety Datalink (VSD) for organic Hg
exposure from Thimerosal in Haemophilus influenzae type b
(Hib)-containing vaccines administered at specific times with-
in the first 15 months of life among subjects diagnosed with
pervasive developmental disorder (PDD) (n=534) in compar-
ison to controls. The generally accepted biologically non-
plausible linkage between Thimerosal exposure and subse-
quent diagnosis of febrile seizure (n=5886) was examined as
a control outcome. Cases diagnosed with PDD received sig-
nificantly more organic Hg within the first 6 months of life
(odds ratio (OR)=1.97, p<0.001) and first 15 months of life
(OR=3.94, p<0.0001) than controls, whereas cases diag-
nosed with febrile seizure were no more likely than controls
to have received increased organic Hg. On a per microgram of
organic Hg basis, cases diagnosed with a PDD in comparison
to controls were at significantly greater odds (OR=1.0197,
p<0.0001) of receiving increasing organic Hg exposure with-
in the first 15 months of life, whereas cases diagnosed febrile
seizure were no more likely than controls (OR=0.999,
p>0.20) to have received increasing organic Hg exposure
within the first 15 months of life. Routine childhood
vaccination is an important public health tool to reduce the
morbidity and mortality associated with infectious diseases,
but the present study provides new epidemiological evidence
of a significant relationship between increasing organic Hg
exposure from Thimerosal-containing vaccines and the sub-
sequent risk of PDD diagnosis in males and females.
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Introduction
Thimerosal is an organic mercury (Hg)-containing compound
(49.55 % Hg by weight) historically added to many multi-
dose vials of vaccine as a preservative since the 1930s [1].
Thimerosal is initially metabolized into ethyl-Hg compounds
and thiosalicylate and rapidly binds onto thiol groups found
on many proteins in human blood [2]. It is then actively
transported across the blood brain barrier, including by the
L-type neutral amino acid carrier transport (LAT) system, into
human neuronal cells [3, 4], where it significantly accumu-
lates and persists for many months following exposure and
alters numbers of neurons in the dentate gyrus of the hippo-
campus and thalamus [5, 6].
In 2008, an ecological birth cohort assessment of Thimer-
osal exposure in infants and neurodevelopment disorders
within the computerizedmedical records of the Vaccine Safety
Datalink (VSD) database was undertaken [7]. A total of
278,624 subjects were examined in birth cohorts from 1990–
1996 that had received their first oral polio vaccination by
3 months of age in the VSD. The birth cohort prevalence rate
of the medically diagnosed pervasive developmental disorders
(PDDs) of autism and autism spectrum disorder (ASD) was
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calculated. Exposures to organic Hg from all Thimerosal-
containing vaccines were calculated by birth cohort for spe-
cific exposure windows from birth to 7 months and birth to
13 months of age. Poisson regression analysis was used to
model the association between the prevalence of outcomes
and organic Hg doses from Thimerosal-containing vaccines.
That study found consistent significantly increased rate ratios
for diagnosed autism and ASD with increasing organic Hg
exposure from Thimerosal-containing vaccines from birth to
7 months and birth to 13 months of age.
Subsequently, in 2013, a case-control assessment of organ-
ic Hg from Thimerosal-containing hepatitis B vaccination in
infants who were diagnosed autism in the computerized med-
ical records within the VSD database was undertaken [8].
Subjects diagnosed with autism in comparison to controls
were significantly more likely to have received increased
organic Hg exposure from Thimerosal-containing hepatitis B
vaccines within the first month of life, the first 2 months of
life, and the first 6 months of life.
Finally, and most recently, a case-control study was under-
taken to evaluate the potential dose-response relationship
between organic Hg exposure from Thimerosal-containing
hepatitis B vaccines administered within the first 6 months
of life and the risk of diagnosed PDD [9]. On a per microgram
(μg) of organic Hg basis, cases diagnosed with a PDD were
significantly more likely than controls to have received in-
creased organic Hg from Thimerosal-containing hepatitis B
vaccines administered within the first 6 months of life.
The purpose of the present study was to examine the con-
sistency and extend the previously mentioned studies in the
VSD database by undertaking a case-control study to examine
organic Hg exposure from the administration of Thimerosal in
Haemophilus influenzae type b (Hib)-containing vaccines at
specific times within the first 15 months of life among subjects
diagnosed with a PDD in comparison to controls.
Methods
The study protocol employed was approved by the US Cen-
ters for Disease Control and Prevention (CDC), the Institu-
tional Review Board (IRB) of Kaiser Permanente North-West
(KPNW), and the IRB of Kaiser Permanente Northern Cali-
fornia (KPNC). The data were analyzed at the secure Research
Data Center of the National Center for Health Statistics in
Hyattsville, MD. The views expressed in this study do not
necessarily reflect those of the CDC or those of Kaiser
Permanente.
Determining the Population at Risk
A cohort of over 1.95 million children enrolled in the VSD
project (updated through the end of 2000) from KPNW,
Kaiser Permanente Colorado (KPC), and KPNC were exam-
ined using SAS® software. The VSD project was created in
1991 by the National Immunization Program (NIP) of the
CDC [10–12]. The project links medical event information,
specific vaccine history, and selected demographic informa-
tion from the computerized databases of several Health Main-
tenance Organizations (HMOs). The cohort examined was
comprised of individuals with non-missing date of birth and
non-missing gender, who were continuously HMO enrolled
from their date of birth.
Determining Cases
The outcome files (inpatient and outpatient diagnoses) from
this population were then reviewed to find the first instance of
International Classification of Disease, 9th revision (ICD-9)
diagnosed PDD (ICD-9 code: 299.xx). If there were multiple
instances of the same diagnosis in a child, only the first
instance was counted. All subjects diagnosed with PDD had
to be continuously HMO enrolled from birth until their initial
PDD diagnosis. In addition, only subjects diagnosed with a
PDD following the administration of all the vaccines under
study were included in the present analyses as cases. A total of
534 cases diagnosed with PDD (males=432, females=102,
male/female ratio=4.2:1) born between 1991 and 2000 were
identified. These subjects diagnosed with PDD were evaluat-
ed to determine their age of initial diagnosis of PDD (mean±
standard deviation=4.1±1.56 years old).
In addition, the generally accepted biologically non-
plausible linkage between Thimerosal exposure and subse-
quent diagnosis of febrile seizure was examined as a control
outcome. The outcome files (inpatient and outpatient diagno-
ses) from this population were reviewed to find the first
instance of febrile seizures for each subject defined as 780.3
by ICD-9 coding. If there were multiple instances of the same
diagnosis in a subject, only the first instance was counted. In
addition, only subjects diagnosed with febrile seizures follow-
ing the administration of all the vaccines under study were
included in the present analyses as cases. A total of 5886 cases
diagnosed with febrile seizures (males=3305, females=2581,
male/female ratio=1.3:1) born between 1991 and 2000 were
identified. These subjects diagnosed with febrile seizures were
evaluated to determine their age of initial diagnosis of febrile
seizures (mean±standard deviation=1.54±1.3 years old).
Determining Controls
In order to identify controls without a PDD diagnosis who
would have had only a minimal chance of receiving such a
diagnosis, controls had to have been continuously enrolled
from birth for at least 7.22 years (mean age of initial diagnosis
of PDD +2× standard deviation of mean age of initial diagno-
sis of PDD). Applying this follow-up criterion yielded a total
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of 25,632 controls without a PDD diagnosis (males=13,110,
females=12,522, male/female ratio=1.05) born between 1991
and 1993.
In order to identify controls without a febrile seizure diag-
nosis who would have had only a minimal chance of receiving
such a diagnosis, controls had to have been continuously
enrolled from birth for at least 4.14 years (mean age of initial
diagnosis of febrile seizure +2× standard deviation of mean
age of initial diagnosis of febrile seizure). Applying this
follow-up criterion yielded a total of 85,111 controls without
febrile seizure diagnosis (males=43,615, females=41,496,
male/female ratio=1.05) born between 1991 and 1996.
Thimerosal in Hib-Containing Vaccine Exposure
The vaccine file for cases and controls was then reviewed to
determine the exact dates of Hib-containing vaccine adminis-
tration. Overall, among the cases and controls, Hg exposure
was assigned as follows: 25-μg organic Hg per dose for
whole-cell diphtheria-tetanus-pertussis (DTwP)-Hib vaccine;
25-μg organic Hg per dose for acellular diphtheria-tetanus-
pertussis (DTaP)-Hib vaccine; 25-μg organic Hg per dose for
Hib vaccine manufactured by Lederle, Praxis Biologics, Wy-
eth-Ayerst, or Aventis Pasteur, Inc.; 0-μg organic Hg per dose
for Hib vaccine manufactured byMerck and Company, Inc. or
GlaxoSmithKline; 0-μg organic Hg per dose for Hib-hepatitis
B vaccine; and 0-μg organic Hg per dose for those not
receiving any type of Hib-containing vaccine. The Thimerosal
content for each of the aforementioned vaccines was deter-
mined from the official report by the Committee on Infectious
Diseases and Committee on Environmental Health of the
American Academy of Pediatrics [13].
Statistical Analyses
The Fisher’s exact test statistic and logistic regression statistic
from StatsDirect (Version 2.8.0) were utilized for statistical
analyses, and a two-sided p value <0.05 was considered
statistically significant. In the first case-control experimental
group (experiment I), the data was examined to determine the
frequency of exposure to 50-μg organic Hg from Thimerosal
in Hib-containing vaccines in the first 4 months of life in
comparison to the frequency to 25-μg organic Hg from Thi-
merosal in Hib-containing vaccines in the first 4 months of life
among cases diagnosed with PDD and controls using the
Fisher’s exact test statistic. In the second case-control exper-
imental group (experiment II), the data was examined to
determine the frequency receiving 75-μg organic Hg Thimer-
osal in Hib-containing vaccines within the first 6 months of
life in comparison to the frequency receiving 25-μg organic
Hg from Thimerosal in Hib-containing vaccines in the first
6 months of life among cases and controls using the Fisher’s
exact test statistic. In the third case-control experimental group
(experiment III), the data was examined to determine the
frequency of receiving 100-μg organic Hg Thimerosal Hib-
containing vaccines within the first 15 months of life in
comparison to the frequency of receiving 25-μg organic Hg
in the first 15 months of life from Thimerosal Hib-containing
vaccines among cases and controls using the Fisher’s exact
test statistic. The aforementioned experiments were repeated
when separating the data so that male cases diagnosed with
PDD were compared to male controls (experiments IV–VI)
and female cases diagnosed with PDD were compared to
female controls (experiments VII–IX). In addition, the afore-
mentioned experiments were repeated for the control outcome
of febrile seizure for the diagnosis among cases in comparison
to controls (experiments X–XII) and by comparing cases
diagnosed with PDD to controls with a reduced length of
follow-up (4.11 years in comparison to 7.22 years) (experi-
ments XIII–XV). Finally, the logistic regression statistics were
utilized to determine, among cases diagnosed with PDD in
comparison to controls and among cases diagnosed with
febrile seizures in comparison to controls, the frequency of
receiving increasing doses of organic Hg from Thimerosal in
Hib-containing vaccines administered within the first
15 months of life.
Results
Table 1 displays the relationship between cases diagnosed
with PDD and controls being administered increasing doses
of organic Hg from Thimerosal in Hib-containing vaccines at
several specific points within the first 15 months of life.
Overall, it was observed that cases diagnosed with PDD were
significantly more likely to receive 75-μg organic Hg expo-
sure from Thimerosal in Hib-containing vaccines compared to
25-μg organic Hg exposure from Thimerosal in Hib-
containing vaccines administered within the first 6 months
of life (odds ratio=1.97, p<0.001) and significantly more
likely to receive 100-μg organic Hg exposure from Thimero-
sal in Hib-containing vaccines in compared to 25-μg organic
Hg exposure from Thimerosal in Hib-containing vaccines
administered within the first 15 months of life (odds ratio=
3.94, p<0.0001) than controls.
Tables 2 and 3, respectively, display the relationship be-
tween male cases diagnosed with PDD and male controls and
female cases diagnosed with PDD and female controls being
administered increasing doses of organic Hg exposure from
Thimerosal in Hib-containing vaccines at several specific
points within the first 15 months of life. Male cases diagnosed
with PDD were significantly more likely to receive 75-μg
organic Hg exposure from Thimerosal in Hib-containing vac-
cines in comparison to 25-μg organic Hg exposure from
Thimerosal in Hib-containing vaccines administered within
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Table 1 A summary of organic
Hg exposure from Thimerosal in
Hib-containing vaccines among
cases diagnosed with pervasive
developmental disorders in com-
parison to controls within the
VSD database
1 Controls were enrolled from
birth until at least 7.22 years old
without a pervasive developmen-
tal disorder diagnosis
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Table 2 A summary of organic
Hg exposure from Thimerosal in
Hib-containing vaccines among
male cases diagnosed with perva-
sive developmental disorders in
comparison to male controls
within the VSD database
1 Controls were enrolled from
birth until at least 7.22 years old
without a pervasive developmen-
tal disorder diagnosis
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the first 6 months of life (odds ratio=2.29, p<0.0005) and
significantly more likely to receive 100-μg organic Hg expo-
sure from Thimerosal in Hib-containing vaccines compared to
25-μg organic Hg exposure from Thimerosal in Hib-
containing vaccines administered within the first 15 months
of life (odds ratio=3.98, p<0.0001) than male controls. By
contrast, female cases diagnosed with PDD were only signif-
icantly more likely to receive 100-μg organic Hg exposure
from Thimerosal in Hib-containing vaccines in comparison to
25-μg organic Hg exposure from Thimerosal in Hib-
containing vaccines administered within the first 15 months
of life (odds ratio=3.54, p<0.005).
Table 4 evaluates the relationship between cases diagnosed
with the control outcome of febrile seizure and controls being
administered increasing doses of organic Hg from Thimerosal
in Hib-containing vaccines at several specific points within
the first 15 months of life. Among cases diagnosed with
febrile seizure in comparison to controls, there was no in-
creased frequency of exposure to increasing dosing of organic
Hg from Thimerosal in Hib-containing vaccines administered
at any of the specific periods examined within the first
15 months of life.
Table 5 reveals the potential dose-dependent relationship
between cases diagnosed with PDD in comparison to controls
and cases diagnosed with febrile seizure in comparison to
controls for increasing organic Hg doses from Thimerosal in
Hib-containing vaccines administered within the first
15 months of life. On a per microgram of organic Hg basis,
cases diagnosed with a PDD in comparison to controls were at
significantly greater odds (odds ratio=1.0197, p<0.0001) of
receiving increasing organic Hg exposure from Thimerosal in
Hib-containing vaccines. As a consequence for the maximum
dose of an additional 75-μg organic Hg exposure from Thi-
merosal in Hib-containing vaccines administered within the
first 15 months of life, cases diagnosed with PDD in compar-
ison to controls were 2.478-fold significantly more likely to
receive 100-μg organic Hg from Thimerosal in Hib-
containing vaccines in comparison to 25-μg organic Hg ex-
posure from Thimerosal in Hib-containing vaccines adminis-
tered within the first 15 months of life. By contrast, on a per
microgram of organic Hg basis, cases diagnosed with febrile
seizure in comparison to controls were no more likely (odds
ratio=0.999, p>0.20) of receiving increasing organic Hg ex-
posure from Thimerosal in Hib-containing vaccines.
Table 6 summarizes the discrete point odds ratio estimates
and logistic regression odds ratio estimates for an addi-
tional 25-, 50-, or 75-μg organic Hg from Thimerosal in
Hib-containing vaccines administered within the first
15 months of life among cases diagnosed with a PDD
in comparison to controls. The discrete point odds ratio
estimates and logistic regression odds ratio estimates
were of similar order-of-magnitude for increasing expo-
sure to organic Hg for cases diagnosed with a PDD in
comparison to controls.
Table 3 A summary of organic
mercury exposure from Thimero-
sal in Hib-containing vaccines
among female cases diagnosed
with pervasive developmental
disorders in comparison to female
controls within the VSD database
1 Controls were enrolled from
birth until at least 7.22 years old
without a pervasive developmen-
tal disorder diagnosis
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Discussion
As previously published by investigators from the CDC and
the US Food and Drug Administration (FDA), products, such
as vaccines, which are intended for healthy people, must be
held to a high standard of safety assurance [14]. However,
these previous investigators described that the study of
vaccine risks is more complex than for therapeutic products
because the exposure is nearly universal for many vaccines,
ensuring the chance occurrence of many subsequent tempo-
rally associated adverse outcomes after the administration of
vaccines. As a result, these investigators described using the
VSD, a consortium of HMOs, to more rigorously evaluate
post-vaccination associated risks (hypothesis testing).
Table 4 A summary of organic
Hg exposure from Thimerosal in
Hib-containing vaccines among
cases diagnosed with a febrile
seizure in comparison to controls
within the VSD database
1 Controls were enrolled from
birth until at least 4.14 years old
without a febrile seizure diagnosis
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Table 5 A summary of the po-
tential dose-dependent relation-
ship between exposure to organic
Hg from Thimerosal in Hib-con-
taining vaccines administered
within the first 15 months of life
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The present study revealed cases diagnosed with PDD
were overall, among both male and female cases ana-
lyzed separately, and on a dose-dependent basis, signifi-
cantly more likely than controls to receive increased
organic Hg exposure from Thimerosal in Hib-containing
vaccines administered at specific intervals within the first
15 months of life. The results of the present study are
consistent with and extend the previous ecological birth
cohort study [7] and case-control studies [8, 9] of the
potential relationship between organic Hg exposure from
Thimerosal-containing childhood vaccines and PDD in
the VSD database. The size and magnitude of the ob-
served relationship on a per microgram organic Hg basis
are similar to the previously discussed VSD studies and
suggest that the phenomena observed in the VSD data-
base is more than mere chance. In addition, the signifi-
cant association observed between organic Hg exposure
and subsequently diagnosed PDD is consistent with sev-
eral other studies examining other databases such as the
National Health Interview Survey (NHIS) [15] and the
Vaccine Adverse Event Reporting System (VAERS) [8,
16].
The results of the present study stand in contrast to
six previous epidemiological studies that failed to find a
significant relationship between Hg exposure from
Thimerosal-containing childhood vaccines and diagnosed
PDD [17–22]. As recently reviewed, the aforementioned
studies were found to have significant methodological
concerns, and, as a consequence, their potential ability
to contribute to understanding the potential relationship
between organic Hg exposure from Thimerosal-
containing childhood vaccines and diagnosed PDD was
found to be not interpretable [23].
In further support of the biological plausibility of the
phenomena observed in the present study, investigators
have examined a number of different lines of scientific
inquiry. For example, investigators recently published a
critical review on the mechanisms of how limited thiol
availability, abnormal sulfation chemistry, and decreased
glutathione reserve capacity in children diagnosed with
PDD could make them more susceptible to the toxic effects
of Thimerosal routinely administered as part of childhood
immunization schedules [24]. Another study demonstrated
that human neuronal systems exposed to low concentra-
tions of Thimerosal were able to induce cellular damage
similar to that observed in the neuropathological studies of
subjects diagnosed with a PDD [25]. Finally, several recent
studies of Thimerosal exposure in animal model systems
resulted in neuropathological and behavioral symptoms
similar to those associated with PDD [26–30].
Strengths/Limitations
In considering the strength of the results observed, the VSD
observations made were based upon retrospective assessment
of prospectively collected medical records of patients enrolled
in various HMOs. As such, the VSD data examined were
collected independently of the study design and were, in fact,
collected as part of the routine healthcare individuals received
as part of the participation with their respective HMOs. Thus,
at the times of the collection of these records, the healthcare
providers probably were not thinking about the potential
association between vaccine exposures and potential subse-
quent adverse health outcomes.
The study design used to evaluate the potential relationship
between exposure and outcome was another significant
strength of the present study. Cases examined in the present
study had to be enrolled from birth and were required to be
continuously enrolled until a medical diagnosis of PDD was
made. Moreover, controls had to be enrolled from birth for a
sufficient time period to ensure that there was a very small
chance that, during additional follow-up, any of the controls
would bemedically diagnosedwith a PDD. As a result, factors
associated with enrollment (i.e., adjustment for potential in-
dependent variables between cases and controls were not
necessary because enrollment was from birth) or healthcare-
seeking behavior (i.e., adjustment for potential access/
availability of healthcare was continuous among cases and
Table 6 A summary of exposure to organic Hg from Thimerosal in Hib-containing vaccines administered within the first 15 months of life for the cases
diagnosed with PDD and controls by both the discrete point odds ratio estimates and the logistic regression odds ratio estimates1
Organic Hg exposure level above the reference dose1
Group examined
(ICD-9 Code)
Statistical approach used 25-μg organic Hg (95 % CI) 50-μg organic Hg (95 % CI) 75-μg organic Hg (95 % CI)
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1 The exposure “reference dose” is 25 μg of organic Hg from Thimerosal in Hib-containing vaccines
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controls) were minimized. In addition, cases diagnosed with a
PDD were specifically evaluated to ensure that only those
cases diagnosed with an PDD following vaccine administra-
tion were considered in the present analyses.
An additional strength of the present study is that it was
decided, a priori, to ensure adequate amounts of data for our
analyses and that the included controls would be HMO en-
rolled continuously from birth until they were at least the
mean age of initial diagnosis of PDD plus twice the standard
deviation of the mean age of initial diagnosis of PDD. For
cases diagnosed with a PDD, it was possible to mathematical-
ly evaluate the mean and standard deviation of age for initial
PDD diagnoses within the VSD. From this information, it was
possible to estimate how many additional potential diagnoses
of PDD were missed. It was decided, a priori, to ensure
adequate amounts of data for our analyses and that controls
had to be continuously enrolled in the VSD from birth until
they were at least 7.22 years old (mean age of initial diagnosis
of PDD +2× standard deviation of the mean age of initial
diagnosis of PDD). Based on the data for age of initial diag-
nosis for PDD, this was a sufficient period to ensure that, with
further follow-up, those controls without PDD would proba-
bly not receive a PDD diagnoses in the VSD (mathematically
there is a <2.5 % chance of these individuals being diagnosed
with a PDD with additional follow-up time beyond
7.22 years). As shown in Table 7, when the length of
follow-up of controls examined was reduced to only the mean
age of initial diagnosis of PDD (i.e., cases/controls were
followed for same length of time and mathematically there is
an about 50 % error), the overall adverse effects observed on a
per microgram basis from increasing exposure to organic Hg
exposure from Thimerosal in Hib-containing vaccines complete-
ly disappear. Clearly, these analyses establish the importance of
following controls in any study of PDDs for a sufficient period to
ensure that the risk of a control being subsequently diagnosed
with a “case” condition is as small as possible, subject to the
limitations of the records that are accessible for study.
A further strength of the present study was the specific
methods employed to evaluate differences in cumulative
doses of organic Hg received at specific intervals during the
infant period were not the result of small group of children
receiving anomalous exposure to vaccines. Instead, the sub-
jects examined were exposed to different levels of organic Hg
based upon differences in the Thimerosal content of licensed
Hib vaccines [13] and the recommendations on the ages for
the administration of Hib vaccines to children made by the
1991 Advisory Committee on Immunization Practices recom-
mendations [31].
However, the results of the present study may have a
number of potential limitations. For example, the results ob-
served may have occurred from unknown biases or co-
founders present in the datasets examined. This seems unlike-
ly because the control outcome of febrile seizure (i.e., an
outcome that is not biologically plausibly linked to postnatal
organic Hg exposure from Thimerosal-containing vaccines)
was examined, using the same methodology employed for
Table 7 A summary of organic
Hg exposure from Thimerosal in
Hib-containing vaccines among
cases diagnosed with a PDD in
comparison to controls with a re-
duced length of follow-up1
1 Controls were enrolled from
birth until at least 4.11 years old
without a pervasive developmen-
tal disorder diagnosis
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PDD. As shown in Tables 4 and 5, no similar patterns of
significant associations were observed as those that were found
for organic Hg exposure from Thimerosal in Hib-containing
vaccines and the subsequent risk of PDD diagnosis.
Another potential limitation of the present study is that the
results observed may be the result of statistical chance. Howev-
er, such a possibilitywould be unlikely given the limited number
of statistical tests performed, the highly significant results ob-
served (most p values observed were <0.01), and the consisten-
cy in the direction and magnitude of the results observed. In
addition, it was observed that there were similar order-of-
magnitude odds ratios for increasing organic Hg exposure
among cases diagnosed with a PDD in comparison to controls
for discrete point estimates and logistic regression estimates.
Still, other potential limitations of the present study include
the possibilities that some of the individuals in VSD examined
may have hadmore subtle neurological dysfunction, which was
not brought to the attention of their healthcare providers;
healthcare providers may have misdiagnosed some individuals;
or some vaccine exposures may not have been appropriately
classified. In addition, it is possible that some of the organic Hg
exposures from the Hib-containing vaccines were different than
the estimated amount. For example, ActHIB vaccine
manufactured by Aventis Pasteur was always Thimerosal free,
but it was usually reconstituted with Thimerosal-containing
Tripedia, but it is possible that some doses were reconstituted
with just plain saline. Similarly, some Hib vaccines by Merck
and Company, Inc. may have had 12.5-μg organic Hg per dose,
and not the assigned 0-μg organic Hg per dose. In addition, it is
possible that some very small number of doses of HibTITTER
vaccine manufactured by Lederle may have come in single-
dose vials with 0-μg organic Hg per dose, and not the assigned
25-μg organic Hg per dose. These limitations, while possibly
present in the data examined in the current study, should not
have significantly impacted the results observed because it is
unclear how differential application would have occurred to the
study cohorts examined based upon the Thimerosal doses that
the individuals received. Moreover, misclassification occurring
in the data examined would tend to bias any results observed
toward the null hypothesis, since such effects would result in
individuals being placed in the wrong exposure and/or outcome
categories examined, and result in decreased statistical power to
determine true potential exposure-outcome relationships.
In addition, another potential limitation of the present study
is that exposures to other sources of Hg were not evaluated. At
this time, data analysis restrictions imposed by the CDC
prevent us from studying more than one type of vaccine
subjects received, despite the fact that it is very likely that
the subjects examined incurred other organic Hg exposures
from other Thimerosal-containing childhood vaccines. It is
also likely that subjects examined received Hg exposures from
dental amalgams, fish, or other environmental sources. While
all these other sources of Hg may play a significant
involvement in the pathogenesis PDD, these unaccounted for
Hg exposures would actually tend to bias the results observed
toward the null hypothesis because they potentially would
confound the specific exposure classifications of Hg examined.
For example, individuals classified as having lower organic Hg
exposure from Thimerosal-containing vaccines may have actu-
ally received high doses of Hg from other sources, and indi-
viduals having higher organic Hg exposure from Thimerosal-
containing vaccines may have actually received low doses of
Hg from other sources, with the net result tending to minimize
the magnitude of the associations observed.
It is also possible that the findings reported may be the result
of other components of the vaccines studied, which in isolation
or synergistically interacted with the organic Hg exposures
examined in the present study. These possibilities seem remote,
since multiple different brands of Hib-containing vaccines were
examined (with many different amounts/types of adjuvants and
trace constituents), but a significant overall and dose-dependent
relationship was observed among cases diagnosed with a PDD
in comparison to controls for increasing organic Hg exposure.
Moreover, any effects of other components of vaccines work-
ing in isolation or synergistically would tend to bias the results
observed toward the null hypothesis because they were not
considered in the statistical analyses undertaken.
Additionally, a potential limitation of the present study is
there may be differences in the general health status among the
subjects examined independent of exposure to organic Hg from
Hib-containing vaccine administration. As described previously
by investigators from the CDC [32], confounding of this sort is a
general problem for studies of adverse reactions to prophylactic
interventions, as they may be withheld from some individuals
precisely because they are already at high risk of the adverse
event, and, as a consequence, studies that fail to adequately
control for such confounding factors are likely to underestimate
the risk of adverse events attributable to vaccination. In order to
help minimize that potential effect in our analyses, we utilized a
reference group that received 25 μg organic Hg exposure from
Hib-containing vaccines in all of our statistical analyses. Despite
our attempt to minimize these phenomena in our analyses, we
did observe that there was an apparent protective association for
increased organic Hg exposure from Thimerosal in Hib-
containing vaccines for our control outcome of febrile seizure
compared to controls. As a consequence, there was a “healthy
vaccine” effect in our data. Since this phenomenon is apparent in
the data examined, the significantly increased positive dose-
dependent associations observed for the PDD probably under-
estimates the true extent of the relationship between organic Hg
exposure from Thimerosal in Hib-containing vaccines and the
subsequent PDD outcome studied.
Finally, the current study suffers from the potential limita-
tion that analyses were not conducted to further explore the
precise timing and cumulative doses of organic Hg from all
Thimerosal-containing childhood vaccines associated with
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maximum adverse consequences. In future studies, it would
be worthwhile to further explore these precise-timing and
cumulative-doses phenomena. In addition, it would be valu-
able to evaluate other neurodevelopmental outcomes, as well
as other covariates such as gender, race, birth weight, etc., that
may further affect the magnitude of the adverse effects found.
Conclusion
The present case-control study revealed consistent and signif-
icantly increased associations between exposure to organic Hg
from Thimerosal in Hib-containing vaccines administered at
specific times within the first 15months of life among subjects
(bothmale and female) subsequently diagnosed with a PDD in
comparison to controls. The results also revealed that, on a
dose-dependent basis, subjects diagnosed with a PDD were
significantly more likely than controls to have received in-
creased organic Hg exposure from Thimerosal in Hib-
containing vaccines. The present study is both consistent with
and extends previous epidemiological studies in the VSD
database and provides compelling new epidemiological evi-
dence supporting a significant relationship between increasing
organic Hg exposure from Thimerosal-containing childhood
vaccines and the subsequent risk of a PDD.
As previously described, routine childhood vaccination
may be an important public health tool to reduce the morbidity
and mortality associated with infectious diseases [33]. How-
ever, it is also a public health imperative to end the unneces-
sary addition of organic Hg to vaccines in the form of Thi-
merosal used as a preservative or otherwise, based on data
showing an association between its administration and the
increasing risk for the adverse outcomes studied.
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